Literature DB >> 28066826

Quantification and determinants of the amount of respiratory syncytial virus (RSV) shed using real time PCR data from a longitudinal household study.

Miriam Wathuo1, Graham F Medley2, D James Nokes1,3, Patrick K Munywoki1,4.   

Abstract

Background A better understanding of respiratory syncytial virus (RSV) epidemiology requires realistic estimates of RSV shedding patterns, quantities shed, and identification of the related underlying factors. Methods RSV infection data arise from a cohort study of 47 households with 493 occupants, in coastal Kenya, during the 2009/2010 RSV season. Nasopharyngeal swabs were taken every 3 to 4 days and screened for RSV using a real time polymerase chain reaction (PCR) assay. The amount of virus shed was quantified by calculating the 'area under the curve' using the trapezoidal rule applied to rescaled PCR cycle threshold output. Multivariable linear regression was used to identify correlates of amount of virus shed. Results The median quantity of virus shed per infection episode was 29.4 (95% CI: 15.2, 54.2) log10 ribonucleic acid (RNA) copies. Young age (<1 year), presence of upper respiratory symptoms, intra-household acquisition of infection, an individual's first infection episode in the RSV season, and having a co-infection of RSV group A and B were associated with increased amount of virus shed. Conclusions The findings provide insight into which groups of individuals have higher potential for transmission, information which may be useful in designing RSV prevention strategies.

Entities:  

Keywords:  PCR; RSV; cycle threshold; household; shedding; viral density

Year:  2016        PMID: 28066826      PMCID: PMC5218551          DOI: 10.12688/wellcomeopenres.10284.2

Source DB:  PubMed          Journal:  Wellcome Open Res        ISSN: 2398-502X


Introduction

Respiratory syncytial virus (RSV) is the most common viral cause of severe lower respiratory tract infection (LRTI) among infants and children under 5 years old worldwide, with the greatest burden occurring in developing countries [1]. Most children experience an RSV infection episode by the age of two years, with peak rates of infection occurring in the first year of life [2]. Re-infections occur throughout life [3] as RSV infections provide incomplete or waning immunity. There are no licensed RSV vaccines but there is heightened activity in vaccine development [4– 8]. Vaccine delivery strategies should be informed by detailed understanding of RSV transmission dynamics. To reduce the circulation of RSV, identifying which groups are responsible for majority of the infections is critical. Transmission potential can be estimated by a combination of mixing patterns [9] and virus shedding (viral density and duration). Human experimental infection with RSV reported that volunteers inoculated with a higher dose of virus (4.7 log 10 tissue culture infectious dose (TCID) 50 of RSV A2) were more likely to be infected than those given low doses of the inoculum (3.7 log 10 TCID 50 of RSV A2) [10], suggesting that individuals who shed more virus are likely to be more infectious. Determining quantities shed and the related underlying factors, will help in predicting the spread of infection in a population and identify key groups to target for infection control. Previous studies have used the duration of shedding to identify individuals with the greatest potential for infection spread [11], based on the assumption that they have a higher number of infectious contacts. Several studies report on the duration of RSV shedding with mean values ranging from 4.5 to 11.2 days [12, 13]. In addition to variation in assay type, determinants included history of RSV infection [12], age, infection severity, detection of other viruses before and during the RSV infection, and presence of concurrent RSV infections in the same household [13]. These studies and others [14, 15] do not account for the temporal changes in quantity of virus shed. Experimental RSV infection studies indicate that an individual infection episode begins with low viral shedding, which rises with time as the virus continues to replicate within epithelial cells and finally declines as the infection clears [16]. The current analysis aims to include temporal changes in viral shedding in estimating the total amount of virus shed during an individual RSV infection episode. Relative to the duration of shedding, this may provide an improved correlate of infectiousness and help in identifying the key factors influencing RSV shedding patterns. Such data are informative in formulating vaccine product profiles and designing prevention strategies for RSV.

Methods

Data

The RSV infection data arise from an intensively followed cohort of 47 households with 493 occupants in rural coastal Kenya. The details of the study have been described elsewhere [13, 17, 18]. In summary, throughout an RSV season spanning 26 weeks (December 2009–June 2010), nasopharyngeal swabs (NPS) were collected by trained field assistants every 3–4 days, irrespective of symptoms, from 47 RSV naïve infants and their household members. Households were selected through the Kilifi Health and Demographic Surveillance System (KHDSS) and local community health workers and were considered eligible if they had a child born after 1 st April 2009. The infants were assumed to be RSV naïve because they were born after the 2008/2009 RSV season. A total of 16928 NPS collections were tested for RSV (groups A and B) and other prevalent respiratory viruses (adenoviruses, rhinoviruses and human coronaviruses (NL63, 229E and OC43)) using multiplex real time polymerase chain reaction (PCR) assay as previously described [19]. As PCR cycles proceed the quantity of product detected rises and at some point passes through a user assigned threshold for detection (set at the point of observable exponential rise in product), known as the cycle threshold (Ct). The earlier (lower) the Ct value the higher the starting concentration of target sequence (equated with viral density). As a cut-off, samples with Ct values of 35.0 and below were considered positive. An RSV infection episode was defined as the period within which an individual provided specimens which were PCR positive for the same infecting RSV group with no more than 14 days separating any two positive samples. A household outbreak was defined as a period in which a household experienced more than one individual infection episode, without there being more than 14 days between any two infection episodes. A primary/index case was a person first identified to have an RSV infection leading to a household outbreak. A first episode was the first episode in that season that an individual had while a subsequent episode was a second or third episode that a person may have had during the follow up. Virus test results, recorded in Ct values, were converted to log 10 ribonucleic acid (RNA) copy numbers (direct measure of viral density) to enable plotting of the time – concentration curve. The equation y = -3.308x + 42.9 was used to convert Ct values (y), to their log 10 RNA equivalents (x), as a way of quantifying RNA [20]. The converted values are hereafter referred to as viral densities. Amount of virus shed during an infection episode was estimated by calculating the area under the time-concentration curve (AUC) using the trapezoidal rule [21], with units of copies * days. The peak viral density for each episode was identified as the highest measured viral density in an infection episode.

Calculation of area under curve

For every episode, calculation of the area under the curve involved plotting a time concentration curve of the different log viral densities over the duration of shedding of the episode ( Figure 1). Three scenarios were explored which take account of uncertainty arising from the sampling intervals, estimating a minimum, midpoint and maximum AUC, for which calculations are described below, aided by illustrations in Figure 1A – C. For each scenario, two examples are described: the first with one positive observation, and the second with three positive observations ( Figure 1). This analogy can be extended to episodes with a different number of positive observations. The number of positive observations in an episode ranged from 1 to 11.
Figure 1.

Schema depicting the patterns of virus shedding for three possible scenarios, A, B and C, graphically representing the minimum, midpoint and maximum AUC calculations, respectively, defined in the Methods text. For each scenario two example episodes are shown, the first with only one virus positive sample, and the second with three virus positive samples. Y i – Log viral density values; D A – Day of last negative sample before start of episode; D B – Day of first negative sample after end of episode; D 1 – Day of first positive sample; D 2 – Day of second positive sample; D 3 – Day of third positive sample.

Schema depicting the patterns of virus shedding for three possible scenarios, A, B and C, graphically representing the minimum, midpoint and maximum AUC calculations, respectively, defined in the Methods text. For each scenario two example episodes are shown, the first with only one virus positive sample, and the second with three virus positive samples. Y i – Log viral density values; D A – Day of last negative sample before start of episode; D B – Day of first negative sample after end of episode; D 1 – Day of first positive sample; D 2 – Day of second positive sample; D 3 – Day of third positive sample. The minimum AUC estimate assumed that an individual started shedding on the day of the first positive sample in an infection episode, and stopped shedding on the day of the last positive sample of the episode, in the form shown in Figure 1A, with viral density Y 1(log 10 RNA copies), and hence calculated as, AUC = 0.5 * Y 1 * 1 day. If an episode had two or more consecutive positive observations, AUC was calculated by including all days in which they were assumed to be shedding. Thus, for an example episode with three positive observations, with viral density Y i, i=1,3, respectively, then: AUC = (0.5 *((D 2– D 1) +1) * (Y 1+ Y 2)) + (0.5 * (D 3– D 2) * (Y 2+ Y 3))…………….….. (i). Note the addition of one day to the calculation such that shedding on day 1 is included. Days with zero Ct values in between samples with positive Ct values were taken to have zero viral density, after conversion of the Ct values to log 10 viral RNA copies. Therefore, AUC was calculated as in (i) above including both zero and non-zero observations. For left and right censored episodes, calculation of the amount of virus remained as in (i) above. The midpoint AUC estimate assumed that an individual began shedding midway between the day of the first positive sample of an infection episode and the day of the last negative sample before the start of the episode. An individual was assumed to have stopped shedding midway between the day of the last positive sample of an episode and the day of the first negative sample after the episode ( Figure 1B). Hence to calculate the AUC for an episode with one positive observation: Let the midpoint days be: x = (D A + D 1)/2, and y = (D B + D 1)/2, where D A, D B and D 1 are, respectively, the day of the last negative sample before the start of the episode; day of the first negative sample after the end of the episode; day of the first positive sample, hence AUC = 0.5 *((y – x) + 1) * Y 1. To calculate the AUC for an episode with three positive observations: Let the midpoint days be: x = (D A + D 1)/2, and y = (D B + D 3)/2, where D 2 and D 3 are the days of the second and third positive samples, respectively, so AUC = (0.5 * Y 1 * ((D 1- x) +1)) + (0.5 * (D 2 – D 1) * (Y 1 + Y 2)) + (0.5 * (D 3– D 2) * (Y 2 + Y 3)) + (0.5 * Y 3 * (y - D 3)) …………. (ii). Days with zero Ct values in between samples with positive Ct values were taken to have a Ct value of 40 (the Ct value translating to the lowest viral load), then converted to viral density along with other Ct values in the episode, and the AUC calculated as in (ii) above. For left and right censored episodes, with unknown D A and D B, respectively, shedding was assumed to start 1.85 days (i.e. half the mean sampling interval) before the first observed day of shedding, D 1, and to finish 1.85 days after the last positive sample (D 3 in the example of (ii) above). Hence, in (ii) above, (D 1-x) and (y-D 3) were replaced with the value 1.85 days, for left and right censored data, respectively. To calculate the maximum AUC, individuals were assumed to have begun shedding immediately after the last negative sample before the start of an episode, and stopped shedding immediately before the first negative sample after the episode ( Figure 1C). The viral densities for the days when individuals were considered to have begun and stopped shedding were assumed to be zero. Zero Ct values within an infection episode were assigned viral densities equal to the average recorded for the first positive sample before and firstpositive sample after the zero Ct samples. Hence, to calculate the AUC for an episode with one positive observation: AUC = 0.5 *(D B – D A) * Y 1, and to calculate the AUC for an episode with three positive observations: AUC = (0.5 * Y 1 * (D 1- D A)) + (0.5 * (D 2– D 1) * (Y 1+ Y 2)) + (0.5 * (D 3– D 2) * (Y 2 + Y 3)) + (0.5 * Y 3 * (D B - D 3)) ……………………(iii). Left and right censored episodes were treated similarly to that for midpoint AUC, but assuming shedding began and ended 3.7 days (i.e. the mean sampling interval) before the first positive sample of an episode and after the last positive sample of an episode. Hence in (iii) above, (D 1-D A) and (D B-D 3) were replaced with the value 3.7 days, for left and right censored data, respectively.

Statistical analysis

Data were analysed using Stata version 13.1 (StataCorp. College Station, TX: StataCorp LP. RRID:SCR_012763) and RStudio version 0.99.489 (RStudio Team. RStudio, Inc., Boston, MA. RRID:SCR_000432). The differences in the distribution of amount of virus by various characteristics was tested using the Wilcoxon rank-sum test and Kruskal Wallis test as appropriate. Spearman's rank correlation coefficient was used to find the association between the different measures of viral quantity calculated. Linear regression was used to identify the main factors associated with the amount of virus shed, i.e. AUC. Possible covariates were chosen from the dataset by selecting those that could plausibly be associated with AUC. A univariable analysis was carried out to identify factors associated with AUC. All variables with a p-value of <0.1 in the univariable analysis were included in the multivariable regression analysis. The final multivariable regression model was developed by a backward elimination procedure, removing variables with a p-value >0.05 in each step using likelihood ratio tests. Risk factors were removed in descending order of strength of association determined from the multivariable analysis. Two interactions were tested in the multivariable model. An interaction between age and symptom status was tested to determine if the effect of age on the amount of virus shed varied by symptom status. An interaction between age and primary/secondary case status was also tested because it was suspected that the effect of age on the amount of virus shed could vary by primary/secondary case status. We chose to adjust for sex a priori because it was considered an important risk factor to acute respiratory infections [22]

Ethics

The household study was approved by the KEMRI Ethical Review Committee in Kenya, SSC No. 1651, and the Biomedical Research Ethics Committee at the University of Warwick in the United Kingdom. Data was anonymised by using unique identification numbers for each participant and household.

Consent

Written informed consent was obtained from all participants and/or their parents or guardians.

Results

Infection episodes

The mean (SD) sampling interval was 3.7 (2.3) days. The median number of swabs collected for an individual was 41, with the minimum being 1 swab and the maximum 48 swabs. There were 537 (3.2%) samples from 179 individuals that were positive for RSV. RSV group A only, group B only, and group A/B co-infections were detected in 231 (1.5%), 287 (1.8%), and 19 (0.1%) NPS collections, respectively ( Table 1). From the 179 infected individuals, a total of 208 infection episodes were observed during the six-month study period; 180 were fully observed episodes while 13 and 17 were left and right censored episodes respectively. Two episodes were both left and right censored. Eighty three (39.9%), 111 (53.4%), and 14 (6.7%) episodes were associated with RSV group A, group B and a co-infection respectively. One hundred and fifty two (84.9%) individuals had one episode, while 25 (14.0%) and 2 (1.1%) had two and three episodes respectively ( Table 1). In addition, 24 (60.0%) households had one outbreak, while 5 (12.5%) had two outbreaks.
Table 1.

Distribution of RSV infection episodes among individuals during the 2009/2010 RSV season in a household cohort, coastal Kenya.

CharacteristicCategoriesIndividuals in study (n=493)Individuals infected (n=179)Infection episodes (n=208)Total AUC [a] (n=7875.47)
nn%n%n%
Age at infection<1y553117.33516.82424.130.7
1-<5y824122.95124.52011.825.5
5-<15y1656435.87335.12241.728.4
15-<40y1473519.64019.2854.010.8
> = 40y4484.594.3366.94.6
SexFemale2729653.611856.74392.455.6
Male2218346.49043.33506.244.4
SymptomaticNo877139.79043.32145.227.2
Yes40610860.311856.75753.372.8
Participant in school [b] No25910156.411957.25184.265.6
Yes2047843.68942.82714.434.4
Living with smoker in householdNo38915586.6181877081.289.7
Yes1042413.42713817.310.3
Household size< = 5372212.32512992.612.6
6 to 101805229.16129.32605.333.0
11 to 151013519.64019.21360.517.2
>151757039.18239.42940.137.2
Infection with other virusesNo438346.411052.95054.664.0
Yes4509653.69847.12844.036.0
In household with outbreakNo162147.819292.37460.694.5
Yes33116592.2167.7438.05.5
Infecting RSV group [c] RSV A6636.98339.92838.135.9
RSV B9150.811153.44170.052.8
RSV A & B2212.3146.7890.511.3
Order of the episode in individualFirst15284.917986.17130.390.3
Subsequent2715.12913.9768.39.7
Introducer of RSV infection in householdPrimary case6636.97033.72372.730.0
Others11363.113866.45525.970.0

aTotal amount of virus shed (log 10 RNA copies * days). bIncludes some participants in the age groups 1-<5 years, 5-<15 years, and 15-<40 years only. cIndividuals could appear in one or more categories of this variable.

aTotal amount of virus shed (log 10 RNA copies * days). bIncludes some participants in the age groups 1-<5 years, 5-<15 years, and 15-<40 years only. cIndividuals could appear in one or more categories of this variable.

Overall amount of RSV shed

The amount of virus shed was presented in logarithmic form because the untransformed values were skewed to the right, and the residuals of the linear regression analysis using the untransformed outcome did not meet the normality assumption. Using log transformed values also helped to reduce the variance. The mean (variance) for the untransformed and log-transformed values was 3.73×10 7 (1.34×10 8) and 6.07 (1.51), respectively. The median (interquartile range, IQR) of the amount of virus shed estimated by the minimum, midpoint and maximum AUC approaches was 31.1 (15.4, 57.9), 41.7 (24.3, 68.0), and 50.7 (31.0, 79.6) log 10 RNA copies per infection episode, respectively. The minimum and maximum AUC estimates were strongly correlated with the midpoint AUC estimates (r=0.97 P < 0.001 and r=0.96 P < 0.001, respectively) ( Supplementary Material Figure S1). The alternative measures of RSV shedding, (shedding duration and peak viral density), were also strongly correlated to the midpoint AUC estimates; 0.94 (P < 0.001) and 0.74 (P < 0.001) ( Figure 2). Note, however, that within a narrow range of AUC the range of peak virus can be wide. The distribution of the amount of RSV shed by the various characteristics explored was similar regardless of the estimation method (i.e. minimum, midpoint, or maximum AUC) (See Supplementary Material Table S1) and hereafter only the midpoint estimates are reported. RSV viral loads for both RSV A and RSV B seemed to be low at the beginning of the RSV season, but they later increased well into the season. However, the peak viral loads reached during the season for both RSV A and RSV B seemed to be similar (see Supplementary Material Figure S2).
Figure 2.

Scatter plots showing the correlation between ( a) duration of shedding (days) and ( b) peak viral density (log 10 RNA copies) and midpoint AUC (log 10 RNA copies*days) estimates.

Scatter plots showing the correlation between ( a) duration of shedding (days) and ( b) peak viral density (log 10 RNA copies) and midpoint AUC (log 10 RNA copies*days) estimates.

Amount of RSV shed by various characteristics

The median (IQR) amount of virus shed was 71.0 (42.3, 96.7), 37.7 (24.6, 54.4), 25.0 (14.1, 36.7), 14.6 (9.4, 32.4), and 56.3 (5.7, 65.3) log 10 RNA copies for individuals aged <1y, 1-<5y, 5-<15y, 15-<40y and >=40y respectively ( Figure 3a) based on the midpoint approach, and there was strong evidence of a difference in distribution of AUC in different age groups (P = 0.001). Infection episodes associated with symptoms had a higher median (IQR) amount of virus shed than those without symptoms (42.5 (25.1, 66.0) vs 19.0 (9.8, 29.0) log 10 RNA copies; P < 0.001) ( Figure 3b). Most symptomatic episodes were experienced by younger individuals (<20 years), while older individuals above 20 years mostly had asymptomatic episodes ( Figure 4). Episodes associated with RSV A only, RSV B only, and RSV group A/B co-infection had a median amount of virus of 26.4 (15.1, 52.4), 28.8 (13.2, 48.9), and 66.1 (42.1, 75.5) log 10 RNA copies respectively (P = 0.003) ( Figure 3c). Co-infection (associated with adenoviruses, rhinovirus, or coronaviruses) episodes had a median amount of virus of 38.7 (19.6, 65.3), while episodes not associated with any other infection had a median of 25.0 (11.1, 37.0) log 10 RNA copies, and there was strong evidence (P = 0.003) of a difference in the distribution of AUC in these two groups of episodes. Episodes that occurred during a household outbreak had a median (IQR) amount of virus of 31.6 (15.9, 54.8) log 10 RNA copies, compared to a median (IQR) of 20.3 (10.2, 35.4) log 10 RNA copies for episodes that were not associated with household outbreaks, though there was weak evidence of a difference in medians (see Supplementary Material Table S1). Infants had the highest peak viral density, and longest duration of shedding ( Figure 5). Lowering the threshold below 35 Ct did not greatly change the results but reduced the total number of infections (see Supplementary Material Figure S3).
Figure 3.

Box and whisker plots showing the distribution of amount of virus shed (AUC) using the midpoint estimates by a) age b) symptoms c) RSV type d) order of episode in individual, and e) primary or secondary episode in household. The width of a box relative to other boxes in the same plot is directly proportional to the mean duration of shedding in each category of that plot.

Figure 4.

Scatter plot showing the relationship between midpoint AUC and age stratified by symptom status.

Figure 5.

Scatter plots showing the relationship between duration of shedding (days) and peak viral density (log 10 RNA copies) for individuals aged a) less than 1 year old, b) 1 to 4 years, c) 5 to 14 years, d) 15 to 39 years, and e) 40 years and above.

Box and whisker plots showing the distribution of amount of virus shed (AUC) using the midpoint estimates by a) age b) symptoms c) RSV type d) order of episode in individual, and e) primary or secondary episode in household. The width of a box relative to other boxes in the same plot is directly proportional to the mean duration of shedding in each category of that plot. Scatter plot showing the relationship between midpoint AUC and age stratified by symptom status. Scatter plots showing the relationship between duration of shedding (days) and peak viral density (log 10 RNA copies) for individuals aged a) less than 1 year old, b) 1 to 4 years, c) 5 to 14 years, d) 15 to 39 years, and e) 40 years and above.

Factors associated with the amount of virus shed

The final multivariable regression model identified age, symptom status, RSV infecting group, order of the episode in an individual, and being a primary/secondary case in the household as the main factors associated with the amount of virus shed. The effect of age on the amount of virus shed seemed to vary with primary/secondary case status ( Table 2). The results reported here are, therefore, adjusted for the above covariates. The difference in mean amount of virus in secondary case episodes for age groups 1-<5y, 5-<15y, 15-<40y, and >=40y when compared to infants <1y was; -41.6 (95% CI: -53.7, -29.6), -43.1 (-55.5, -30.7), -50.6 (95% CI: -64.9, -36.3), and -29.4 (95% CI: -50.8, -8.1) log 10 RNA copies respectively (P < 0.001). There was no evidence (p=0.594) of a difference in amount of virus by age for primary cases. There was an increase in mean amount of virus for symptomatic episodes compared to asymptomatic episodes by 14.1 (95% CI: 6.3, 21.9) log 10 RNA copies, and strong evidence of a difference in means (P < 0.001). Mean amount of virus shed for subsequent episodes of individuals in the study RSV season compared to first infections was -10.4 (95% CI: -20.0, -0.8) log 10 RNA copies (P = 0.03). The difference in mean amount of virus for episodes of RSV B only and RSV A/B co-infections when compared to episodes of RSV group A only was 3.7 (95% CI: -3.1, 10.5) log 10 RNA copies, and 21.3 (95% CI: 7.3, 35.3) log 10 RNA copies (P = 0.012) respectively ( Table 2). For all age groups, there was no evidence of a difference in amount of virus between primary and secondary episodes. There was no evidence that the effect of age on amount of virus varied by symptom status.
Table 2.

Factors influencing amount of virus shed in rural coastal Kenya during the 2009/2010 RSV season: Multiple linear regression analysis.

FactorsCategoriesBeta [a] (log 10 RNA copies)95% CIP-value
Primary cases: Age in years <1yRef *
1-<5y-0.21-18.4, 17.90.594
5-<15y-7.3-23.0, 8.4
15-<40y-12.7-30.7, 5.2
> = 40y-9.4-39.3, 20.5
Secondary cases: Age in years <1yRef *
1-<5y-41.6-53.7, -29.6<0.001
15-<15y-43.1-55.5, -30.7
15-<40y-50.6-64.9, -36.3
>=40y-29.4-50.8, -8.1
Symptomatic NoRef *
Yes14.16.3, 21.9<0.001
Order of infection in individual FirstRef *
Subsequent-10.4-20.0, -0.80.03
RSV group RSV ARef * 0.012
RSV B3.7-3.1, 10.5
Co-infection21.37.3, 35.3
Sex FemaleRef * 0.287
Male-4.0-10.2, 3.0

aDifference in mean AUC in comparison to reference category using midpoint estimates. *Reference category.

aDifference in mean AUC in comparison to reference category using midpoint estimates. *Reference category.

Discussion

We report a detailed analysis of RSV shedding patterns in which the amount of virus shed during the course of an infection was quantified, and factors associated with the quantity shed were identified. Young age at infection, presence of respiratory symptoms, intra-household acquisition of infection, being a first infection episode in the season for an individual, and having a co-infection were associated with increased amounts of RSV shed. The majority of virus available for transmission during an RSV epidemic appears to arise from individuals in their first year of life and therefore undergoing their first RSV infection episode (since all were born after the preceding RSV epidemic). Household size did not influence the per person amount of virus shed, and neither did the presence of a smoker in the household. In this rural community, indoor smoke from solid fuels (mainly firewood and charcoal) was ubiquitous and likely to conceal any specific effects of cigarette smoke. In addition, we only had 18 smokers out of the 493 participants. So, relatively few people lived with smokers. Also, we did not collect data on contact patterns of household members with the smokers or if the smoker did smoke in the house or outside which could affect the level of exposure to smoke within the households. The apparent effect of school going status on amount of virus shed was confounded by age, as school was attended by young individuals, who in turn shed more virus. RSV viral densities appeared to be low for most individuals in the beginning of the season but increased well into the season. This was a reflection of the occurrence of the RSV epidemic. Viral densities for RSV B were first to increase followed by viral densities for RSV A. RSV B infections spread to more individuals probably due to earlier onset by chance compared to RSV A infections. The finding that 90.3% of virus shed was from individuals experiencing their first episode in the RSV season indicates that first infections are most important in virus transmission compared to subsequent infections ( Table 1). Modelling studies have been unable to determine to what extent reinfections contribute to transmission [11, 23], which has a big influence on predictions of the effect of vaccination on transmission dynamics [11]. Whilst these results do not include the opportunities to transmit, which will be generally higher for school-going children undergoing their second or third infection [9], they suggest that people with their first episode in the season are the most likely to transmit infection when they contact susceptible individuals. Peak viral density and duration of infection episodes were highly correlated with the amount of virus shed. Infants had the highest peak viral density, and longest duration of shedding ( Figure 5). Infants shed the highest median amount of virus followed by individuals aged 40 and above. The adults (15 to 39 years) shed the lowest amounts ( Figure 3a). Acquired immunity (following exposure to RSV) and physiological development of the airways with age have been linked with reduced risk of severe RSV disease [12, 13]. We speculate that elderly individuals are more prone to infection because of their deteriorating immune response which could explain the higher amount of virus in individuals over 40 years, compared to other adults. However, this study cannot discriminate between the two factors of young age and a first infection as the dominant factors associated with shedding (infants all had first infections, and we do not know the history of previous infection in all other ages). Individuals with a co-infection of RSV group A and B shed twice the amount of virus compared to those infected with either RSV A or B only, suggesting that the physiological infection processes for two viruses might be independent (rather than competitive or synergistic). Similar patterns of shedding were reported based on shedding duration estimates using this dataset [13] and others [12, 15]. These findings can provide a hint to pathogenesis of RSV disease [6]. A recent experimental study has reported disease severity to be closely related to viral load [16] even though another shows contrasting observations on disease severity and viral load link [10]. Our study showed a strong positive association between virus shedding and presence of respiratory symptoms. Symptomatic individualso shed higher amounts of virus than asymptomatic individuals irrespective of age. Overall those who were both young (<5 years) and symptomatic contributed to the highest amount of virus shed (51.8%). Using amount of virus as a correlate of infectiousness, these two factors are associated with virus spread within the community and in families and thus have direct implications in design and delivery of transmission-blocking interventions such as vaccines. This analysis had some limitations. First, the nasal samples were collected with intervals of 3 to 4 days hence a complete profile of the viral density changes over time could not be captured. This has implications on the accuracy of our AUC estimates. However we minimize this by using a conservative approach providing three possible estimates i.e. minimum, midpoint and maximum estimates as detailed in the Supplementary Material. Furthermore, the three measures were strongly correlated and their variations by various characteristics such as age and symptoms, were comparable. Second, Ct values were converted to RNA copies using published associations [20] hence providing only a relative measure of virus density in the sample taken rather than absolute values of the amount of virus shed. Using the inverse of the Ct values as a measure of viral load did not change the distribution of AUC by various characteristics or any conclusions made from the results. There are no published studies using our approach in a community setting to facilitate comparison. Our approach takes into account both changing viral load and the duration of shedding making it more robust. However, its accuracy also relies on user selected thresholds for measures of viral load, and this could result in some differences in findings across studies. A quantitative PCR would be preferable. Third, there is inherent variability in estimated viral load due to variation (both biological and methodological) in the amount of virus collected using a nasopharyngeal swab. Deep NPS collections might have a higher density than perinasal swabs but events prior to sampling, e.g. sneezing, might introduce variations in sample quality. However this is likely to be non-systematic hence only conservatively affects our final conclusions. Finally, the assumption is made that virus density as measured by PCR is a measure of infectious virus. The most likely limitation of this assumption is over-estimating the duration of and peak shedding of viable virus. Generally, the relationship between the measures of viral shedding and infectiousness to other people are unknown. In the current analysis we took logarithms of estimated viral densities, under the general assumption that the risk of transmission will saturate at higher viral shedding. We then integrated over this logarithmic measure to obtain a measure of total infectiousness. An alternative would be to have integrated over the untransformed viral density, and then taken logarithms prior to statistical analysis. This approach did not give substantially different results. Estimation of the functional relationship between viral shedding and transmission is being considered in on-going analysis of the epidemics observed within households. In conclusion, long shedders tend to shed more virus and are likely to be more infectious. However, it is also evident that individuals with similar durations of shedding may shed different amounts of virus. Individuals with a combination of high viral density and long shedding durations are likely to shed the most virus. This improves on existing literature that measures infectiousness using the duration of shedding only. The groups that are most likely to spread infection are individuals with a first infection episode, the symptomatic, and most predominantly, the young, which has implications on which groups to target for vaccination in RSV prevention strategies.

Data availability

The dataset used in this study, together with associated analysis code (.do), graphics code (.R), variable codebook (.pdf), and summary file (.txt) are available from Harvard Dataverse: doi: 10.7910/DVN/MOTEJH [24]. The dataset has restricted access, retaining Personal Identifiable Information (specifically dates) for analysis duplication. Please request access as instructed in the Readme.txt file. Other files are open access. This is a report that adds significantly to the medical literature on the subject. It is from a well-designed study from a longitudinal community household study in rural Kenya from whom collections of respiratory secretions were collected with and without bias with respect to symptomatology. As such, it is a very valuable database to assess many important clinical questions. These authors attempt to leverage this impressive dataset to evaluate quantitative virology relationships to clinical and epidemiological endpoints. This is a very valuable goal and they have generated results and analyses that are important, however, there are numerous problems with this approach which deserve to be reviewed, and their conclusions need to be modified in light of these limitations. Relatively non-quantitative collection technique: Unfortunately, because of the nature of the study (outpatient from village homes), the collections themselves had to be performed using a swab technique. Swab collections (even if done using a deep swab approach) have been shown to produce specimens that are difficult to use for quantitative virology. Variations in depth of swab acquisition, variations in depth of the transition zone from squamous to respiratory epithelial cells within the nose, reduced sensitivity caused by the small volume collection and the large volume dilution required during the nucleic acid extraction technique, and sample to sample variations of the PCR technique (which can not be overcome by re-running the specimen because of lack of sufficient collection volume) all contribute to creating this relatively non-quantitative collection technique. Relatively non-quantitative PCR techniques employed: Molecular quantification of viruses within a sample requires a standard curve to assign a quantitative value based upon a Ct value. One cannot use the Ct value itself without it being read from a standard curve. These standard curves can be created externally from the PCR run itself (less desirable) or can be created internally during the actual run which includes the unknown samples from the patients themselves (more desirable). The creation and design of the standard curves is extremely important in determination of quantification and can be based on whole viral genome from infected cells (thereby controlling for the nucleic acid extraction and purification steps, and controlling for the reverse transcriptase step). Less optimal (but much easier to construct) standard curves can be created that utilize cloned cDNA (easily giving a copy number, but not properly controlling for either the nucleic acid extraction, purification, nor reverse transcription steps). Unfortunately, this study apparently has not constructed standard curves, and they rely solely on generated Ct values to imply quantity. It is, in some cases, acceptable to do so when using a single-plex assay (where relative viral concentrations can fairly be compared to the same technique on different specimens). But this approach is never acceptable to use when multiplexed assays are employed (see below). Introduction of technique-driven systemic bias in molecular quantification: This molecular quantification bias comes in two forms: A) multiplex-PCRs detect viral amplicon differently when there are two molecular targets within the same sample based on competition for ions, primers, and probes, and enzymes within the reaction. B) The relative amplification efficiency (and the probe-binding-induced fluorescent signal read out by the PCR machine, will be different depending on the probe and the amplicon size and the relative binding efficiencies of the forward and reverse primers. This makes it impossible to quantitatively assess the quantification of two different viruses (RSV-A and B) within a mixed sample and also makes it impossible to compare one target’s quantity (RSV-A) with another target’s quantity (RSV-B). Failure to evaluate infectious viral particles and using non-infectious viral particle counts to make conclusions about infectious viral load. The authors find and conclude that: “The majority of virus available for transmission during an RSV epidemic appears to arise from individuals in their first year of life and therefore undergoing their first RSV infection episode.” Although I agree with this statement, it is important to realize that from data within this manuscript itself, this statement assumes that infectious viral particles equate to quantitative PCR copy number. This assumption is certainly not true. Infectious virus particles are best quantified by a quantitative culture approach. Factors within the respiratory secretions themselves (such as IgA) have been shown to be associated with RSV culture negativity despite persistent high concentrations of RSV genome continuing to be detected within human respiratory secretions after a documented RSV infection [1] , [2]. Infant’s ability to generate RSV-specific IgA is significantly less than the ability of adults to do so during an RSV infection [3] , [4]. The author’s conclusion that infants likely contribute more than do adults to epidemic spread of RSV infection has been carefully modeled in a recent paper [5] in which two key factors; infectious viral particle quantity over time, and quantitative measures of human contact activity during times of infection, were incorporated into the model. The implications of these factors promoting RSV community spread should influence the types of RSV vaccines to be developed and the age ranges targeted by these vaccines, and these different vaccine scenarios have been modeled [5]. Questions regarding viral load area under the curve calculations. Any area is geometrically and mathematically defined by multiplying two linear dimensions together. The same is true for viral load area under the curve (in this paper it is called viral density area under the curve for some reason). Viral load AUC is Viral load (units) multiplied by Time (units). The resulting units of viral load are always containing the unit of time. (For example “log PFUe x days”, or “Copies x hours”). The units of viral load AUC in this paper are incorrect and need to be redefined. When one realizes the mathematical definition of AUC, then it is no surprise that Fig 2a and 2b show a lot of correlation between duration of shedding and AUC (because time (duration) is actually in the denominator of the AUC value). Problems of determining co-infection with RSV-A and RSV-B. Students of RSV need to be very careful in reporting and interpreting data regarding co-infections. This paper is no exception. This paper and others assume that when a multiplexed assay reports that the wavelength of the excited probe is orange and another wavelength of the excited probe is green (I am giving a hypothetical example) that this means that both RSV-A and B are present in the sample. However this may or may not be the case. For example, if the virus is an RSV-A virus, the probe for RSV-A binds relatively tightly to the amplicon through strict base-pair matching, and then cleavage of the reporter molecule from the quencher molecule allows the detection of the amplicon (through inhibition of FRET). However, it is very possible that the RSV-B probe will also bind to the amplicon at a certain number of base pairs, and this can result in the RSV-B reporter being detected (erroneously causing the authors to read that RSV-B is also present in the sample). Because of this problem, this paper’s results, analyses, and conclusions regarding “co-infections” of RSV-A and B need to be taken with caution. Problems with co-infections with RSV and other respiratory viruses (Adeno, Rhinoviruses, and Coronaviruses). RSV infection causes massive shedding of respiratory epithelial cells into the airway lumen (which are then collected by the swab technique). Any persistent virus present in those shed cells will therefore be detected at higher frequency during an RSV infection. This is an alternative explanation of the correlation between viral load of RSV and detection of these other infections (Top of Pg. 8). This phenomenon carries much different implications than are assumed to be present by these authors. Associations with age and outcome (area under the curve viral load). The authors do an excellent job of assessing the associations between area under the curve and other factors. After observing the problems with the actual viral load area under the curve measurements themselves, (see points 1,2,3,5 above) it appears that their data shows that the primary host characteristic that affects area under the curve viral load is whether or not children have had a prior RSV infection. This fits with other data from the literature. However, it would be nice to know whether young age within the infant age category was predictive of increased area under the curve viral load. Unfortunately, the data set does not contain data on age in weeks, days, or months within the first year of life. I suspect that younger ages within the infant age range, i.e. the RSV-naïve population, will be related to the area under the curve viral load. Other databases will likely need to be leveraged in order to determine this important question. Although the number of infant infections in this database will likely be small, the authors should attempt to break down the ages within the infant age range in order to try to answer this important question. The infant antiviral functional immune response is likely not fully developed at birth, and RSV can be used to interrogate the ontogeny of this immune response [6], which can have major implications on vaccine development. Associations with other factors and outcome (area under the curve viral load). The manuscript also indicates that presence of respiratory symptoms, intra-household acquisition of infection, being a first infection episode in the season for an individual, and having a co-infection were associated with increased amounts of RSV shed. We should think about the root causes of these associations so that we can understand principles of RSV infection. I do not know the intricacies of the subject acquisition and identification, but is it possible that intra-household transmission simply is a surrogate marker for earlier swabbing of the patient? We know that viral load peaks in the nose shortly after symptom onset, and that viral load declines thereafter. Therefore, having a first swab earlier would create a subject with a greater viral load AUC. An alternative explanation is that perhaps an inoculum effect is present and that children are inoculated within a household transmission with greater amounts of virus, thus causing greater AUC viral load. Past studies have tried to determine an inoculum effect for RSV and crowding does not seem to be a predictor of viral load [7] , [8]. Likewise, in experimental RSV infection models of adults, there appears to be little effect of inoculum on AUC viral load [2]. It is likely that RSV inoculum affects whether a person becomes infected, but once that person is infected that inoculum has little effect on viral load, AUC or disease severity. I have addressed the issue of co-infection (and alternative explanations for the observed data) in points 6 and 7 above. Waning control of RSV infection with advanced age. Perhaps the greatest contribution of this paper to the medical literature is the finding that area under the curve viral load begins to rise again in adulthood after the age of 40. This is a fascinating finding, and could result from either immune senescence, or reduced exposure to boosting infections of RSV, or a combination of both.  Whether this adult age-related increase in RSV area under the curve viral load is similar in developed countries will need to be evaluated. Overall this paper adds significantly to the medical literature into our understanding of RSV in communities. These authors should be lauded and encouraged in their efforts to extract as much information as possible from carefully constructed clinical trials. I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. 1. Relatively non-quantitative collection technique: Unfortunately, because of the nature of the study (outpatient from village homes), the collections themselves had to be performed using a swab technique. Swab collections (even if done using a deep swab approach) have been shown to produce specimens that are difficult to use for quantitative virology. Variations in depth of swab acquisition, variations in depth of the transition zone from squamous to respiratory epithelial cells within the nose, reduced sensitivity caused by the small volume collection and the large volume dilution required during the nucleic acid extraction technique, and sample to sample variations of the PCR technique (which can not be overcome by re-running the specimen because of lack of sufficient collection volume) all contribute to creating this relatively non-quantitative collection technique. 2. Relatively non-quantitative PCR techniques employed: Molecular quantification of viruses within a sample requires a standard curve to assign a quantitative value based upon a Ct value. One cannot use the Ct value itself without it being read from a standard curve. These standard curves can be created externally from the PCR run itself (less desirable) or can be created internally during the actual run which includes the unknown samples from the patients themselves (more desirable). The creation and design of the standard curves is extremely important in determination of quantification and can be based on whole viral genome from infected cells (thereby controlling for the nucleic acid extraction and purification steps, and controlling for the reverse transcriptase step). Less optimal (but much easier to construct) standard curves can be created that utilize cloned cDNA (easily giving a copy number, but not properly controlling for either the nucleic acid extraction, purification, nor reverse transcription steps). Unfortunately, this study apparently has not constructed standard curves, and they rely solely on generated Ct values to imply quantity. It is, in some cases, acceptable to do so when using a single-plex assay (where relative viral concentrations can fairly be compared to the same technique on different specimens). But this approach is never acceptable to use when multiplexed assays are employed (see below). 3. Introduction of technique-driven systemic bias in molecular quantification: This molecular quantification bias comes in two forms: A) multiplex-PCRs detect viral amplicon differently when there are two molecular targets within the same sample based on competition for ions, primers, and probes, and enzymes within the reaction. B) The relative amplification efficiency (and the probe-binding-induced fluorescent signal read out by the PCR machine, will be different depending on the probe and the amplicon size and the relative binding efficiencies of the forward and reverse primers. This makes it impossible to quantitatively assess the quantification of two different viruses (RSV-A and B) within a mixed sample and also makes it impossible to compare one target’s quantity (RSV-A) with another target’s quantity (RSV-B). 4. Failure to evaluate infectious viral particles and using non-infectious viral particle counts to make conclusions about infectious viral load. The authors find and conclude that: “The majority of virus available for transmission during an RSV epidemic appears to arise from individuals in their first year of life and therefore undergoing their first RSV infection episode.” Although I agree with this statement, it is important to realize that from data within this manuscript itself, this statement assumes that infectious viral particles equate to quantitative PCR copy number. This assumption is certainly not true. Infectious virus particles are best quantified by a quantitative culture approach. Factors within the respiratory secretions themselves (such as IgA) have been shown to be associated with RSV culture negativity despite persistent high concentrations of RSV genome continuing to be detected within human respiratory secretions after a documented RSV infectionInfant’s ability to generate RSV-specific IgA is significantly less than the ability of adults to do so during an RSV infection. The author’s conclusion that infants likely contribute more than do adults to epidemic spread of RSV infection has been carefully modeled in a recent paper in which two key factors; infectious viral particle quantity over time, and quantitative measures of human contact activity during times of infection, were incorporated into the model. The implications of these factors promoting RSV community spread should influence the types of RSV vaccines to be developed and the age ranges targeted by these vaccines, and these different vaccine scenarios have been modeled. 5. Questions regarding viral load area under the curve calculations. Any area is geometrically and mathematically defined by multiplying two linear dimensions together. The same is true for viral load area under the curve (in this paper it is called viral density area under the curve for some reason). Viral load AUC is Viral load (units) multiplied by Time (units). The resulting units of viral load are always containing the unit of time. (For example “log PFUe x days”, or “Copies x hours”). The units of viral load AUC in this paper are incorrect and need to be redefined. When one realizes the mathematical definition of AUC, then it is no surprise that Fig 2a and 2b show a lot of correlation between duration of shedding and AUC (because time (duration) is actually in the denominator of the AUC value). 6. Problems of determining co-infection with RSV-A and RSV-B. Students of RSV need to be very careful in reporting and interpreting data regarding co-infections. This paper is no exception. This paper and others assume that when a multiplexed assay reports that the wavelength of the excited probe is orange and another wavelength of the excited probe is green (I am giving a hypothetical example) that this means that both RSV-A and B are present in the sample. However this may or may not be the case. For example, if the virus is an RSV-A virus, the probe for RSV-A binds relatively tightly to the amplicon through strict base-pair matching, and then cleavage of the reporter molecule from the quencher molecule allows the detection of the amplicon (through inhibition of FRET). However, it is very possible that the RSV-B probe will also bind to the amplicon at a certain number of base pairs, and this can result in the RSV-B reporter being detected (erroneously causing the authors to read that RSV-B is also present in the sample). Because of this problem, this paper’s results, analyses, and conclusions regarding “co-infections” of RSV-A and B need to be taken with caution. 7. Problems with co-infections with RSV and other respiratory viruses (Adeno, Rhinoviruses, and Coronaviruses). RSV infection causes massive shedding of respiratory epithelial cells into the airway lumen (which are then collected by the swab technique). Any persistent virus present in those shed cells will therefore be detected at higher frequency during an RSV infection. This is an alternative explanation of the correlation between viral load of RSV and detection of these other infections (Top of Pg. 8). This phenomenon carries much different implications than are assumed to be present by these authors. 8. Associations with age and outcome (area under the curve viral load). The authors do an excellent job of assessing the associations between area under the curve and other factors. After observing the problems with the actual viral load area under the curve measurements themselves, (see points 1,2,3,5 above) it appears that their data shows that the primary host characteristic that affects area under the curve viral load is whether or not children have had a prior RSV infection. This fits with other data from the literature. However, it would be nice to know whether young age within the infant age category was predictive of increased area under the curve viral load. Unfortunately, the data set does not contain data on age in weeks, days, or months within the first year of life. I suspect that younger ages within the infant age range, i.e. the RSV-naïve population, will be related to the area under the curve viral load. Other databases will likely need to be leveraged in order to determine this important question. Although the number of infant infections in this database will likely be small, the authors should attempt to break down the ages within the infant age range in order to try to answer this important question. The infant antiviral functional immune response is likely not fully developed at birth, and RSV can be used to interrogate the ontogeny of this immune response, which can have major implications on vaccine development. 9. Associations with other factors and outcome (area under the curve viral load). The manuscript also indicates that presence of respiratory symptoms, intra-household acquisition of infection, being a first infection episode in the season for an individual, and having a co-infection were associated with increased amounts of RSV shed. We should think about the root causes of these associations so that we can understand principles of RSV infection.I do not know the intricacies of the subject acquisition and identification, but is it possible that intra-household transmission simply is a surrogate marker for earlier swabbing of the patient? We know that viral load peaks in the nose shortly after symptom onset, and that viral load declines thereafter. Therefore, having a first swab earlier would create a subject with a greater viral load AUC. An alternative explanation is that perhaps an inoculum effect is present and that children are inoculated within a household transmission with greater amounts of virus, thus causing greater AUC viral load. Past studies have tried to determine an inoculum effect for RSV and crowding does not seem to be a predictor of viral load. Likewise, in experimental RSV infection models of adults, there appears to be little effect of inoculum on AUC viral load. It is likely that RSV inoculum affects whether a person becomes infected, but once that person is infected that inoculum has little effect on viral load, AUC or disease severity. I have addressed the issue of co-infection (and alternative explanations for the observed data) in points 6 and 7 above. 10. Waning control of RSV infection with advanced age. Perhaps the greatest contribution of this paper to the medical literature is the finding that area under the curve viral load begins to rise again in adulthood after the age of 40. This is a fascinating finding, and could result from either immune senescence, or reduced exposure to boosting infections of RSV, or a combination of both.  Whether this adult age-related increase in RSV area under the curve viral load is similar in developed countries will need to be evaluated. DeVincenzo, J. P., T. Wilkinson, A. Vaishnaw, J. Cehelsky, R. Meyers, S. Nochur, L. Harrison, P. Meeking, A. Mann, E. Moane, J. Oxford, R. Pareek, R. Moore, E. Walsh, R. Studholme, P. Dorsett, R. Alvarez and R. Lambkin-Williams (2010). "Viral load drives disease in humans experimentally infected with respiratory syncytial virus." Am J Respir Crit Care Med 182(10): 1305-1314. The report by the KEMRI team builds on a cohort of 47 households followed through an RSV season in coastal Kenya with frequent nasopharyngeal swabs for detection of RSV. The introduction and rationale for the study are very clearly provided. More complicated is the analysis to determine minimum and maximum areas under the curve representing estimates of the total amount of virus shed based on a PCR cycle to detection of virus. Once this is accepted the analysis of factors influencing the amount of virus detected is straightforward and indicates age, symptoms, RSV type B, and whether infection is the initial infection during the sampling period. Each of these observations remained significant in a multiple linear regression analysis. None of these observations are surprising but all are of interest in this locale and within a community based study design. Might the large number of asymptomatic individuals include some who subsequently became symptomatic and were at the time of sampling in the incubation period of their illness? The authors address some limitations of the study. Other things that might be considered include an analysis based gradation of symptoms in terms of virus recovered, whether frequency of sampling was influenced by symptoms, and patterns of spread within families. The latter is of particular interest in that I suspect that with many viral infections the peak titre will influence spread more than the total amount shed. The number of days to detection of secondary infections in the household might give a clue to the validity of this hypothesis. I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. 1. Might the large number of asymptomatic individuals include some who subsequently became symptomatic and were at the time of sampling in the incubation period of their illness? 2. Other things that might be considered include an analysis based gradation of symptoms in terms of virus recovered, whether frequency of sampling was influenced by symptoms, and patterns of spread within families. This is an interesting paper using area under curve (AUC), derived from non-quantitative PCR data using three different estimates, as a unit to measure viral shedding during an RSV season 8 years ago for a prospective cohort of 47 households in rural coastal Kenya. AUC can take variability of viral load due to different factors (technical, biological) into account and reflects the overall temporal changes of virus shed. The authors use three models for calculating the AUC. While this is not my expertise, I cannot comment on these models, but I strongly believe that choosing an appropriate model is one of the most crucial parts of this study, any wrong assumption/ formula of these models will affect the results and its interpretations. Hence, the introduction of AUC as a measurement unit for transmission studies is an interesting concept, however, it may need a validation step using data from animal models, human challenge models, or clinical data monitoring RSV load. Below are some points requiring more clarification: Specific minor comments:  In summary, this paper reports important data on RSV transmission in a community setting; data on this subject is still scarce. This data is relevant for RSV vaccine and treatment development and can help suggest target groups for vaccination and implications of infection control measurement. The interval between samples is 3-4 day, why did the author choose this big interval, while previous human challenge studies have suggested daily sampling or every 2 days could be the best follow-up (1). This is a major limitation as samples are taken only every 3-4 days and amounts of shed virus are therefore modelled based on little data and many assumptions, which may or may not equal out. The authors should definitely include more information on how their semi-quantitative data was calibrated. As authors didn’t use qPCR and use of a standard curve is not described, authors should clarify how they ensured PCR efficiency was stable between runs and what was used to calibrate runs and Ct values. This is a crucial thing to add, as all results in this paper are based on (semi)quantitative measurements and therefore, proper quantification is absolutely key. At the beginning of the Methods section, the authors specified that the AUC was calculated using viral load in log scale, but later for the midpoint AUC, they used Ct-value, please clarify. Reference 21 and 23 are not accessible Without baseline demographics about the sampled cohort I find some of this information hard to interpret. Symptomatic infections would also be interesting to see by age group. In Table 1, it is not clear how the total AUC was calculated. Surprisingly, the number of RSV infection episodes in the young age group (less than 1 year old and less than 5 years old) is much lower (denominator?) than those in the age group of 5-15 years old, while many epidemiological data have shown the re-infection rates are higher in the young age group. There is no comment/discussion on this result. In addition, the number of RSV infection episodes and the AUC in “living with smokers” group were lower and similar, respectively, compared to those who do not live with smokers. This result is controversial with the common observations from many epidemiological studies on RSV susceptibility and there is no comment/discussion regarding this. P3c1p2: The comparison with human volunteer studies to suggest load / inoculum may be associated with infection is not very strong, this may only be true in the background of a well-developed immune history against RSV whereas the main burden of disease of RSV is in infants who will not have this history yet. P3c1p3: I don’t think excretion is proper terminology for the process of virus shedding (nor is viral density – which is used later on, p6). P3c1p4: the number of sampled household members and the inclusion criteria should be added here. P3c2p1: why were only adeno, corona and rhino targeted with the diagnostic PCR and not the influenzas, parainfluenzas and hMPV? This is a very limited definition of co-infection. P6: Please clarify why data are presented as median (IQR) amounts of virus shed in one paragraph but then as mean amounts (95%CI) of virus shed in the other. P8c1p2: In Table 2 sex is not significant, but its mentioned here as an associated factor. P8c2p3: the result that timing within the season was (appeared?) associated with the amount of virus shed is presented in the discussion section, shouldn’t this also be presented as a result, with data and a p-value? P8c2p3: why is it of particular importance that 90.3% of virus shed is from individuals experiencing their first episode? Also, 179/208 episodes studied were first episodes. Table 2: the number of primary and secondary cases per age group would be informative here We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above. 1. The interval between samples is 3-4 day, why did the author choose this big interval, while previous human challenge studies have suggested daily sampling or every 2 days could be the best follow-up (1). This is a major limitation as samples are taken only every 3-4 days and amounts of shed virus are therefore modelled based on little data and many assumptions, which may or may not equal out. The authors should definitely include more information on how their semi-quantitative data was calibrated. 2. As authors didn’t use qPCR and use of a standard curve is not described, authors should clarify how they ensured PCR efficiency was stable between runs and what was used to calibrate runs and Ct values. This is a crucial thing to add, as all results in this paper are based on (semi) quantitative measurements and therefore, proper quantification is absolutely key. 3. At the beginning of the Methods section, the authors specified that the AUC was calculated using viral load in log scale, but later for the midpoint AUC, they used Ct-value, please clarify. 4. Reference 21 and 23 are not accessible 5. Without baseline demographics about the sampled cohort, I find some of this information hard to interpret. Symptomatic infections would also be interesting to see by age group. 6.  In Table 1, it is not clear how the total AUC was calculated. Surprisingly, the number of RSV infection episodes in the young age group (less than 1 year old and less than 5 years old) is much lower (denominator?) than those in the age group of 5-15 years old, while many epidemiological data have shown the re-infection rates are higher in the young age group. There is no comment/discussion on this result. 7. In addition, the number of RSV infection episodes and the AUC in “living with smokers” group were lower and similar, respectively, compared to those who do not live with smokers. This result is controversial with the common observations from many epidemiological studies on RSV susceptibility and there is no comment/discussion regarding this. Specific minor comments: 1. P3c1p2: The comparison with human volunteer studies to suggest load / inoculum may be associated with infection is not very strong, this may only be true in the background of a well-developed immune history against RSV whereas the main burden of disease of RSV is in infants who will not have this history yet. 2. P3c1p3: I don’t think excretion is proper terminology for the process of virus shedding (nor is viral density – which is used later on, p6) 3. P3c1p4: the number of sampled household members and the inclusion criteria should be added here. 4. P3c2p1: why were only adeno, corona and rhino targeted with the diagnostic PCR and not the influenzas, parainfluenzas and hMPV? This is a very limited definition of co-infection. 5. P6: Please clarify why data are presented as median (IQR) amounts of virus shed in one paragraph but then as mean amounts (95%CI) of virus shed in the other 6. P8c1p2: In Table 2 sex is not significant, but its mentioned here as an associated factor 7. P8c2p3: the result that timing within the season was (appeared?) associated with the amount of virus shed is presented in the discussion section, shouldn’t this also be presented as a result, with data and a p-value? 8. P8c2p3: why is it of particular importance that 90.3% of virus shed is from individuals experiencing their first episode? Also, 179/208 episodes studied were first episodes 9. Table 2: the number of primary and secondary cases per age group would be informative here . This is an interesting manuscript about RSV shedding, in the context of household transmission. There are few data on this topic in the literature and this is a valuable contribution. I thought the manuscript was clear and well written and should be indexed. I only had one comment: Please comment on the choice of log viral load in analyses In Figure 1 please clarify the y-axis metric and you might like to explain this choice as well. Is it viral density (copies), or log_10 copies ? It seems as if you are calculating the AUC based on log_10 viral copies but what is the biological interpretation of that? I was wondering whether the number of viruses could be a better correlate of transmission, not their log? I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. 1. Please comment on the choice of log viral load in analyses 2. In Figure 1 please clarify the y-axis metric and you might like to explain this choice as well. Is it viral density (copies), or log_10 copies? 3. It seems as if you are calculating the AUC based on log_10 viral copies but what is the biological interpretation of that? I was wondering whether the number of viruses could be a better correlate of transmission, not their log?
  27 in total

1.  Quantification of mRNA using real-time RT-PCR.

Authors:  Tania Nolan; Rebecca E Hands; Stephen A Bustin
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

2.  Effect of Preexisting Serum and Mucosal Antibody on Experimental Respiratory Syncytial Virus (RSV) Challenge and Infection of Adults.

Authors:  Bindiya Bagga; Jeffrey E Cehelsky; Akshay Vaishnaw; Tom Wilkinson; Rachel Meyers; Lisa M Harrison; Philippa L Roddam; Edward E Walsh; John P DeVincenzo
Journal:  J Infect Dis       Date:  2015-05-14       Impact factor: 5.226

3.  Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.

Authors:  Ruth A Karron; Peter F Wright; Robert B Belshe; Bhagvanji Thumar; Roberta Casey; Frances Newman; Fernando P Polack; Valerie B Randolph; Anne Deatly; Jill Hackell; William Gruber; Brian R Murphy; Peter L Collins
Journal:  J Infect Dis       Date:  2005-03-01       Impact factor: 5.226

4.  Vaccine Induced Herd Immunity for Control of Respiratory Syncytial Virus Disease in a Low-Income Country Setting.

Authors:  Timothy M Kinyanjui; Thomas A House; Moses C Kiti; Patricia A Cane; David J Nokes; Graham F Medley
Journal:  PLoS One       Date:  2015-09-21       Impact factor: 3.240

5.  Quantifying age-related rates of social contact using diaries in a rural coastal population of Kenya.

Authors:  Moses Chapa Kiti; Timothy Muiruri Kinyanjui; Dorothy Chelagat Koech; Patrick Kiio Munywoki; Graham Francis Medley; David James Nokes
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

6.  Frequent Asymptomatic Respiratory Syncytial Virus Infections During an Epidemic in a Rural Kenyan Household Cohort.

Authors:  Patrick K Munywoki; Dorothy C Koech; Charles N Agoti; Ann Bett; Patricia A Cane; Graham F Medley; D James Nokes
Journal:  J Infect Dis       Date:  2015-05-04       Impact factor: 5.226

7.  Quantification and determinants of the amount of respiratory syncytial virus (RSV) shed using real time PCR data from a longitudinal household study.

Authors:  Miriam Wathuo; Graham F Medley; D James Nokes; Patrick K Munywoki
Journal:  Wellcome Open Res       Date:  2016-12-14

8.  WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015.

Authors:  Kayvon Modjarrad; Birgitte Giersing; David C Kaslow; Peter G Smith; Vasee S Moorthy
Journal:  Vaccine       Date:  2015-06-20       Impact factor: 3.641

9.  Duration of shedding of respiratory syncytial virus in a community study of Kenyan children.

Authors:  Emelda A Okiro; Lisa J White; Mwanajuma Ngama; Patricia A Cane; Graham F Medley; D James Nokes
Journal:  BMC Infect Dis       Date:  2010-01-22       Impact factor: 3.090

Review 10.  Strategic priorities for respiratory syncytial virus (RSV) vaccine development.

Authors:  L J Anderson; P R Dormitzer; D J Nokes; R Rappuoli; A Roca; B S Graham
Journal:  Vaccine       Date:  2013-04-18       Impact factor: 3.641

View more
  8 in total

Review 1.  Polymicrobial Interactions Operative during Pathogen Transmission.

Authors:  Hannah M Rowe; Jason W Rosch
Journal:  mBio       Date:  2021-05-18       Impact factor: 7.867

2.  Quantification and determinants of the amount of respiratory syncytial virus (RSV) shed using real time PCR data from a longitudinal household study.

Authors:  Miriam Wathuo; Graham F Medley; D James Nokes; Patrick K Munywoki
Journal:  Wellcome Open Res       Date:  2016-12-14

3.  Continuous Invasion by Respiratory Viruses Observed in Rural Households During a Respiratory Syncytial Virus Seasonal Outbreak in Coastal Kenya.

Authors:  Patrick K Munywoki; Dorothy C Koech; Charles N Agoti; Patricia A Cane; Graham F Medley; D James Nokes
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

4.  Use of the moving epidemic method (MEM) to assess national surveillance data for respiratory syncytial virus (RSV) in the Netherlands, 2005 to 2017.

Authors:  Laura M Vos; Anne C Teirlinck; José E Lozano; Tomás Vega; Gé A Donker; Andy Im Hoepelman; Louis J Bont; Jan Jelrik Oosterheert; Adam Meijer
Journal:  Euro Surveill       Date:  2019-05

5.  Risk factors and patterns of household clusters of respiratory viruses in rural Nepal.

Authors:  E M Scott; A Magaret; J Kuypers; J M Tielsch; J Katz; S K Khatry; L Stewart; L Shrestha; S C LeClerq; J A Englund; H Y Chu
Journal:  Epidemiol Infect       Date:  2019-10-14       Impact factor: 2.451

6.  Targeted antiviral treatment using non-ionizing radiation therapy for SARS-CoV-2 and viral pandemics preparedness: Technique, methods and practical notes for clinical application.

Authors:  Ayan Barbora; Refael Minnes
Journal:  PLoS One       Date:  2021-05-14       Impact factor: 3.240

7.  Model-based estimates of transmission of respiratory syncytial virus within households.

Authors:  Ivy K Kombe; Patrick K Munywoki; Marc Baguelin; D James Nokes; Graham F Medley
Journal:  Epidemics       Date:  2018-12-15       Impact factor: 4.396

8.  Recommendations for respiratory syncytial virus surveillance at the national level.

Authors:  Anne C Teirlinck; Eeva K Broberg; Are Stuwitz Berg; Harry Campbell; Rachel M Reeves; AnnaSara Carnahan; Bruno Lina; Gatis Pakarna; Håkon Bøås; Hanna Nohynek; Hanne-Dorthe Emborg; Harish Nair; Janine Reiche; Jesus Angel Oliva; Joanne O'Gorman; John Paget; Karol Szymanski; Kostas Danis; Maja Socan; Manuel Gijon; Marie Rapp; Martina Havlíčková; Ramona Trebbien; Raquel Guiomar; Siddhivinayak S Hirve; Silke Buda; Sylvie van der Werf; Adam Meijer; Thea K Fischer
Journal:  Eur Respir J       Date:  2021-10-01       Impact factor: 16.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.